3.14
Precedente Chiudi:
$3.23
Aprire:
$3.2395
Volume 24 ore:
11,626
Relative Volume:
0.64
Capitalizzazione di mercato:
$4.61M
Reddito:
$8.62M
Utile/perdita netta:
$-6.15M
Rapporto P/E:
-0.2847
EPS:
-11.03
Flusso di cassa netto:
$-5.32M
1 W Prestazione:
+1.62%
1M Prestazione:
+40.81%
6M Prestazione:
-44.42%
1 anno Prestazione:
-44.91%
Evoke Pharma Inc Stock (EVOK) Company Profile
Nome
Evoke Pharma Inc
Settore
Telefono
858-345-1494
Indirizzo
420 STEVENS AVENUE, SOLANA BEACH, CA
Confronta EVOK con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
EVOK
Evoke Pharma Inc
|
3.14 | 4.61M | 8.62M | -6.15M | -5.32M | -11.03 |
![]()
ZTS
Zoetis Inc
|
159.27 | 70.23B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
HLN
Haleon Plc Adr
|
10.74 | 48.23B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 48.22B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.93 | 18.57B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
301.42 | 13.29B | 2.76B | 1.11B | 898.10M | 22.77 |
Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2020-06-22 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
2019-03-05 | Downgrade | H.C. Wainwright | Buy → Neutral |
2018-03-08 | Reiterato | B. Riley FBR, Inc. | Buy |
2017-10-19 | Ripresa | FBR & Co. | Buy |
2017-03-16 | Reiterato | Rodman & Renshaw | Buy |
2017-01-30 | Aggiornamento | Laidlaw | Neutral → Buy |
2017-01-05 | Aggiornamento | Rodman & Renshaw | Neutral → Buy |
2016-12-23 | Reiterato | Rodman & Renshaw | Neutral |
2016-07-19 | Reiterato | FBR Capital | Outperform |
2016-07-19 | Downgrade | Noble Financial | Buy → Hold |
2016-07-18 | Downgrade | Rodman & Renshaw | Buy → Neutral |
2016-03-16 | Iniziato | Northland Capital | Outperform |
2016-03-14 | Reiterato | Ascendiant Capital Markets | Buy |
2016-02-17 | Ripresa | FBR Capital | Outperform |
2014-12-03 | Reiterato | MLV & Co | Buy |
2014-11-07 | Iniziato | MLV & Co | Buy |
2014-04-22 | Iniziato | Laidlaw | Buy |
2013-11-19 | Iniziato | Aegis Capital | Buy |
Mostra tutto
Evoke Pharma Inc Borsa (EVOK) Ultime notizie
Evoke Pharma (NASDAQ:EVOK) Now Covered by Analysts at StockNews.com - Defense World
StockNews.com Initiates Coverage on Evoke Pharma (NASDAQ:EVOK) - Defense World
Evoke Pharma (EVOK) to Present Key Metoclopramide Study at DDW 2025 | EVOK Stock News - GuruFocus
Evoke Pharma to Present New Data Comparing Tardive Dyskinesia In - GuruFocus
Evoke Pharma Announces Presentation of New Research on Tardive Dyskinesia at Digestive Disease Week 2025 - Nasdaq
Hudbay Signs Exploration Agreement with the Mosakahiken Cree Nation for the Talbot Deposit in Manitoba - The Manila Times
Evoke Pharma to Present New Data Comparing Tardive - GlobeNewswire
Groundbreaking Safety Analysis: How 100M+ Patient Study Could Reshape Metoclopramide Treatment Guidelines - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Functional Dyspepsia Drug Industry Report 2025-2034: Market Dynamics, Trends, and Forecasts - WhaTech
Evoke Pharma, Inc. (NASDAQ:EVOK) Short Interest Update - Defense World
FY2025 Earnings Estimate for TSE:MNO Issued By Cormark - Defense World
Top Market Trend Impacting Digestive and Intestinal Remedies Development in the Coming Years:Technological ... - WhaTech
Evoke Pharma stock hits 52-week low at $2.01 amid downturn By Investing.com - Investing.com South Africa
Evoke Pharma stock hits 52-week low at $2.01 amid downturn - Investing.com India
Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2024 Earnings Call Transcript - MSN
StockNews.com Begins Coverage on Evoke Pharma (NASDAQ:EVOK) - Defense World
US Reciprocal Tariffs Evoke Mixed Response From India Inc - Free Press Journal
Is The Market Punishing Lynch Group Holdings Limited (ASX:LGL) For Its Mixed Fundamentals? - AInvest
Gastroparesis Market Growth to Accelerate in Forecast Period - openPR.com
Evoke Pharma stock hits 52-week low at $2.43 amid challenges By Investing.com - Investing.com South Africa
Evoke Pharma stock hits 52-week low at $2.43 amid challenges - Investing.com India
Short Interest in Evoke Pharma, Inc. (NASDAQ:EVOK) Declines By 32.7% - Defense World
Tenaz Energy Corp. (OTCMKTS:ATUUF) Short Interest Update - Defense World
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Evoke Pharma (NASDAQ:EVOK) Shares Cross Below 200 Day Moving Average – Here’s Why - Defense World
Evoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.com - Defense World
Bleichroeder LP Significantly Reduces Stake in Evoke Pharma Inc - GuruFocus
Bleichroeder LP's Strategic Acquisition of Evoke Pharma Inc Shar - GuruFocus.com
Evoke Pharma stock hits 52-week low at $3.4 amid challenges - Investing.com Australia
Evoke Pharma stock hits 52-week low at $3.4 amid challenges By Investing.com - Investing.com South Africa
Market Cool On Evoke Pharma, Inc.'s (NASDAQ:EVOK) Revenues Pushing Shares 29% Lower - Simply Wall St
Evoke Pharma, Inc. (NASDAQ:EVOK) Just Reported And Analysts Have Been Cutting Their Estimates - Yahoo Finance
EVOKEvoke Pharma Inc Latest Stock News & Market Updates - Stock Titan
Earnings call transcript: Evoke Pharma Q4 2024 reports strong sales growth - Investing.com Australia
Evoke Pharma’s Earnings Call Highlights Revenue Growth and Strategic Partnerships - TipRanks
Evoke Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Evoke Pharma Inc (EVOK) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Growth Plans - Yahoo
Evoke Pharma Reports Strong Revenue Growth in 2024 - TipRanks
Evoke Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Marketscreener.com
EVOKE PHARMA Earnings Results: $EVOK Reports Quarterly Earnings - Nasdaq
Evoke Pharma Inc Azioni (EVOK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):